Krsnaa DiagnosticsQ4 FY24

Krsnaa Diagnostics Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹518.7P/E: 16.7Market Cap: ₹1.7K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • Krsnaa Diagnostics targets a robust revenue growth with a CAGR of approximately 25%-30% over the next 2-5 years.
  • FY’24 revenue was INR 620 crores with 27% YoY growth; strong momentum expected to continue.
  • Expansion is focused on radiology and pathology, with a 60:40 radiology to pathology mix anticipated.
  • New tenders and projects, especially in radiology (CT scans, MRIs), will drive incremental growth.
  • B2C business is an emerging segment expected to grow steadily, starting from around 2%-3% of revenue.
  • Mature PPP centers typically achieve higher margins and stable revenue growth after 3 years.
  • Investments in infrastructure and new capabilities are expected to convert into higher volumes and stable EBITDA margins (~25%) as projects mature.

See what Krsnaa Diagnostics management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • The company aims to maintain existing debt levels around INR53 crores as of March 2024 and does not foresee significant increases in the near term.
  • Debt discussed primarily relates to short-term working capital needs due to increased receivables and investment in capital expenditure (e.g., down payments on equipment).
  • Management’s stance is to try to be debt-free but expects to maintain manageable debt levels given business growth dynamics.
  • There is no explicit mention of any immediate or planned equity fundraising in the disclosed discussions.
  • Future decisions on capital expenditure, such as in the event of winning the Rajasthan project, will dictate if incremental borrowing is needed.
  • Some pay-per-use agreements initiated with partners aim to expand operations without heavy debt or asset commitments.

See what Krsnaa Diagnostics management said on order book — free account, 30 seconds.

Capex plans

Yes
  • FY '25 and FY '26 capex is expected around INR 150 crores, excluding Rajasthan.
  • If Rajasthan project comes through, capex could increase to around INR 250 crores (INR 50 crores incremental).
  • Exact Rajasthan capex to be clarified once project details are finalized.
  • Focus on asset-light model for B2C expansion, leveraging existing lab infrastructure with minimal incremental capex.
  • Investments include setting up of new pathology labs and deployment of radiology equipment such as CT scans and MRIs.
  • Maharashtra: 10 CT scans operationalized; 29 more to be operationalized soon with revenue expected from Q2 FY '25.
  • Continuous investment in quality accreditations like CAP and expanding test menu.
  • Plans to maintain debt levels to support capex and working capital needs without significant increase in overall debt.

Track Krsnaa Diagnostics — get its next earnings analysis in your feed

How does Krsnaa Diagnostics rank vs peers in Healthcare Services?

Pro feature
ThisKrsnaa Diagnostics
Rev 2Mar 3

How does Krsnaa Diagnostics rank in Healthcare Services?

Compare Krsnaa Diagnostics against every Healthcare Services company (Q4 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →